Airway Epithelium Gene Expression: AEGIS IDE

NCT00746759 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1331

Last updated 2015-06-04

No results posted yet for this study

Summary

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Conditions

Interventions

DEVICE

Biomarker (not used as an intervention)

This study is an observational study. There is no intervention.

Sponsors & Collaborators

  • University of Pennsylvania

    collaborator OTHER
  • Columbia University

    collaborator OTHER
  • Temple University

    collaborator OTHER
  • Indiana University

    collaborator OTHER
  • University of Alabama at Birmingham

    collaborator OTHER
  • University of Missouri-Columbia

    collaborator OTHER
  • Louisiana State University Health Sciences Center in New Orleans

    collaborator OTHER
  • University of Wisconsin, Madison

    collaborator OTHER
  • Medical University of South Carolina

    collaborator OTHER
  • National Jewish Health

    collaborator OTHER
  • Overlake Hospital Bellevue WA

    collaborator UNKNOWN
  • Pulmonary and Allergy Associates of New Jersey

    collaborator UNKNOWN
  • Pulmonary Associates of Arizona

    collaborator UNKNOWN
  • William Jennings Bryan Dorn VA Medical Center

    collaborator FED
  • Virginia Commonwealth University

    collaborator OTHER
  • Jamaica Hospital Medical Center

    collaborator OTHER
  • North Florida/South Georgia Veterans Health System

    collaborator OTHER
  • Steward St. Elizabeth's Medical Center of Boston, Inc.

    collaborator OTHER
  • University of California, Davis

    collaborator OTHER
  • Yale University

    collaborator OTHER
  • The Cleveland Clinic

    collaborator OTHER
  • Allegro Diagnostics, Corp.

    lead INDUSTRY

Principal Investigators

  • Duncan Whitney, PhD · Allegro Diagnostics

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-12-31
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00746759 on ClinicalTrials.gov